Marit M. Melssen

994 total citations
20 papers, 695 citations indexed

About

Marit M. Melssen is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Marit M. Melssen has authored 20 papers receiving a total of 695 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Immunology, 17 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in Marit M. Melssen's work include Immunotherapy and Immune Responses (13 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Immune Cell Function and Interaction (7 papers). Marit M. Melssen is often cited by papers focused on Immunotherapy and Immune Responses (13 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Immune Cell Function and Interaction (7 papers). Marit M. Melssen collaborates with scholars based in United States, Sweden and Netherlands. Marit M. Melssen's co-authors include Craig L. Slingluff, Katie M. Leick, Natasha Sheybani, Víctor H. Engelhard, Ileana S. Mauldin, Max O. Meneveau, Robin S. Lindsay, Anthony B. Rodriguez, Samuel Young and Amber N. Woods and has published in prestigious journals such as Journal of Clinical Investigation, The Journal of Immunology and Cancer Cell.

In The Last Decade

Marit M. Melssen

19 papers receiving 688 citations

Peers

Countries citing papers authored by Marit M. Melssen

Since Specialization

Citations

This map shows the geographic impact of Marit M. Melssen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marit M. Melssen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marit M. Melssen more than expected).

Fields of papers citing papers by Marit M. Melssen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marit M. Melssen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marit M. Melssen. The network helps show where Marit M. Melssen may publish in the future.

Co-authorship network of co-authors of Marit M. Melssen

This figure shows the co-authorship network connecting the top 25 collaborators of Marit M. Melssen. A scholar is included among the top collaborators of Marit M. Melssen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marit M. Melssen. Marit M. Melssen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Protocol for in vivo immune cell analysis in subcutaneous murine tumor models using advanced flow cytometry 2025 ·STAR Protocols ·(unknown), Marit M. Melssen, Diana Spiegelberg	1
2	MDM2/MDMX inhibition by Sulanemadlin synergizes with anti-Programmed Death 1 immunotherapy in wild-type p53 tumors 2024 ·iScience ·(unknown), Marit M. Melssen, Pavitra Kannan, Arun Chandramohan, Anthony W. Partridge, (unknown), (unknown), David P. Lane, Marika Nestor, Diana Spiegelberg	8
3	Barriers to immune cell infiltration in tumors 2023 ·Journal for ImmunoTherapy of Cancer ·Marit M. Melssen, Natasha Sheybani, Katie M. Leick, Craig L. Slingluff	80
4	FPR2 Shapes an Immune-Excluded Pancreatic Tumor Microenvironment and Drives T-cell Exhaustion in a Sex-Dependent Manner 2023 ·Cancer Research ·Fei He, (unknown), (unknown), (unknown), Sayaka Suzuki, Tianjie Liu, Qi Wang, Carlos Fernández Moro, (unknown), Peter Olofsson, Marit M. Melssen, Siu Kwan Sze, Mikael Björnstedt, Matthias Löhr, Mikael C. I. Karlsson, Rainer Heuchel, Dhifaf Sarhan	12
5	Endothelial VEGFR2-PLCγ signaling regulates vascular permeability and antitumor immunity through eNOS/Src 2023 ·Journal of Clinical Investigation ·Elin Sjöberg, Marit M. Melssen, Mark Richards, (unknown), (unknown), Dongying Chen, Emmanuel Nwadozi, (unknown), Dominic Love, Takeshi Ninchoji, Masabumi Shibuya, Michael Simons, Anna Dimberg, Lena Claesson‐Welsh	27
6	NK cells reduce anergic T cell development in early-stage tumors by promoting myeloid cell maturation 2022 ·Frontiers in Oncology ·Robin S. Lindsay, Marit M. Melssen, (unknown), (unknown), Amber N. Woods, Anthony B. Rodriguez, Michael G. Brown, Víctor H. Engelhard	3
7	An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes 2022 ·Cancer Cell ·(unknown), Akanksha Verma, Ruth Dannenfelser, Marit M. Melssen, Itay Tirosh, Benjamin Izar, Tae‐Gyun Kim, Christopher J. Nirschl, K. Sanjana P. Devi, Walter C. Olson, Craig L. Slingluff, Víctor H. Engelhard, Levi A. Garraway, Aviv Regev, Kira Minkis, Charles H. Yoon, Olga G. Troyanskaya, Olivier Elemento, Mayte Suárez‐Fariñas, Niroshana Anandasabapathy	39
8	Peptide emulsions in incomplete Freund’s adjuvant create effective nurseries promoting egress of systemic CD4⁺ and CD8⁺ T cells for immunotherapy of cancer 2022 ·Journal for ImmunoTherapy of Cancer ·Marit M. Melssen, (unknown), Craig L. Slingluff, Cornelis J.M. Melief	24
9	Differential Expression of CD49a and CD49b Determines Localization and Function of Tumor-Infiltrating CD8+ T Cells 2021 ·Cancer Immunology Research ·Marit M. Melssen, Robin S. Lindsay, (unknown), Anthony B. Rodriguez, (unknown), Salwador Cyranowski, Melanie R. Rutkowski, Mark R. Conaway, Cornelis J.M. Melief, Sjoerd H. van der Burg, Ukpong B. Eyo, Craig L. Slingluff, Víctor H. Engelhard	15
10	Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts 2021 ·Cell Reports ·Anthony B. Rodriguez, J. David Peske, Amber N. Woods, Katie M. Leick, Ileana S. Mauldin, Max O. Meneveau, Samuel Young, Robin S. Lindsay, Marit M. Melssen, Salwador Cyranowski, (unknown), Mark R. Conaway, Yang‐Xin Fu, Craig L. Slingluff, Víctor H. Engelhard	159
11	Characterization and comparison of innate and adaptive immune responses at vaccine sites in melanoma vaccine clinical trials 2021 ·Cancer Immunology Immunotherapy ·Marit M. Melssen, (unknown), Max O. Meneveau, Mark E. Smolkin, Joel Pinczewski, Alexander F. Koeppel, Stephen Turner, Katia Sol‐Church, (unknown), Donna H. Deacon, Gina R. Petroni, Craig L. Slingluff	13
12	Incomplete Freund’s adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment 2020 ·Journal for ImmunoTherapy of Cancer ·(unknown), Max O. Meneveau, Marit M. Melssen, Kevin Lynch, Alexander F. Koeppel, Samuel Young, Stephen Turner, Pankaj Kumar, Katia Sol‐Church, Ileana S. Mauldin, Craig L. Slingluff	23
13	Immune Mechanisms Orchestrate Tertiary Lymphoid Structures in Tumors Via Cancer-Associated Fibroblasts 2020 ·SSRN Electronic Journal ·Anthony B. Rodriguez, J. David Peske, Amber N. Woods, Katie M. Leick, Ileana S. Mauldin, Samuel Young, Robin S. Lindsay, Marit M. Melssen, Salwador Cyranowski, (unknown), Max O. Meneveau, Mark R. Conaway, Yang‐Xin Fu, Craig L. Slingluff, Víctor H. Engelhard	21
14	Vaccine Strategy in Melanoma 2019 ·Surgical Oncology Clinics of North America ·(unknown), Katie M. Leick, Marit M. Melssen, Craig L. Slingluff	22
15	A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund’s adjuvant in melanoma patients 2019 ·Journal for ImmunoTherapy of Cancer ·Marit M. Melssen, Gina R. Petroni, Kimberly A. Chianese‐Bullock, Nolan A. Wages, William W. Grosh, Nikole Varhegyi, Mark E. Smolkin, Kelly T. Smith, (unknown), Donna H. Deacon, Elizabeth Gaughan, Craig L. Slingluff	74
16	The Barrier Molecules Junction Plakoglobin, Filaggrin, and Dystonin Play Roles in Melanoma Growth and Angiogenesis 2019 ·Annals of Surgery ·Katie M. Leick, Anthony B. Rodriguez, Marit M. Melssen, Mouadh Benamar, Robin S. Lindsay, (unknown), (unknown), Mahmut Parlak, Tarek Abbas, Víctor H. Engelhard, Craig L. Slingluff	16
17	Formation and phenotypic characterization of CD49a, CD49b and CD103 expressing CD8 T cell populations in human metastatic melanoma 2018 ·OncoImmunology ·Marit M. Melssen, Walter C. Olson, Nolan A. Wages, Brian J. Capaldo, Ileana S. Mauldin, (unknown), (unknown), Cornelis J.M. Melief, Timothy N. J. Bullock, Víctor H. Engelhard, Craig L. Slingluff	12
18	Cellular and molecular mechanisms regulating the development of tertiary lymphoid structures in tumor 2018 ·The Journal of Immunology ·Anthony B. Rodriguez, J. David Peske, Amber N. Woods, Marit M. Melssen, Salwador Cyranowski, (unknown), Víctor H. Engelhard	1
19	Vaccines targeting helper T cells for cancer immunotherapy 2017 ·Current Opinion in Immunology ·Marit M. Melssen, Craig L. Slingluff	145
20	CD49a and CD103 expression on tumor infiltrating lymphocytes in B16-OVA tumors depends on location and is correlated with a naive phenotype 2016 ·The Journal of Immunology ·Marit M. Melssen, Anthony B. Rodriguez, Craig L. Slingluff, Víctor H. Engelhard	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact